Advertisement

Picture [iito] Männer Ballett 650x80px
Product › Details

SeroTag® Autoantibody Profiling

Products Next higher product group biomarker discovery technology_o
Period Status 2013-12-03 production/use existent
Organisation Organisation Protagen AG
  Today Oncimmune Germany GmbH
     

Protagen AG. (12/3/13). "Press Release: Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases". Dortmund.

Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, "The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team."


About Protagen

PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.


Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T: +49 (0) 231 9742 6300
F: +49 (0) 231 9742 6301
bd@protagen.com

Press Inquiries
Dr. Georg Lautscham
CBO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T:+49 (0) 231 9742 6300
F:+49 (0) 231 9742 6301
bd@protagen.com

   
Record changed: 2019-03-24

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for SeroTag® Autoantibody Profiling


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top